Palliation of malignant ascites. Issue 1 (22nd March 2019)

• Record Type: Journal Article
• Authors: Hodge, Caitlin; Badgwell, Brian D.
• Is Part Of: Journal of surgical oncology. Volume 120:Issue 1(2019)
• Page Start: 67
• Page End: 73
• Publication Date: 2019-03-22
• Subjects: catumaxomab -- hyperthermic intraperitoneal chemotherapy -- paracentesis -- peritoneal carcinomatosis; Cancer -- Surgery -- Periodicals; Neoplasms -- Periodicals; 616
• DOI: 10.1002/jso.25453
• Languages: English
• ISSNs: 0022-4790

Abstract

Abstract: Malignant ascites (MA) carries a poor prognosis. It can have a significant impact on quality of life (QOL), with increasing abdominal distention, pain, and dyspnea. Diuretics typically do not work well for MA. Paracentesis is effective in providing temporary symptom relief but requires frequent repeat procedures. Options for durable symptom management include indwelling catheters, peritoneal ports, peritoneovenous shunts, intraperitoneal (i.p.) catumaxomab, and hyperthermic i.p. chemotherapy. These interventions do not necessarily improve overall survival but may improve QOL.